Rita A. Karachun

Senior Vice President-Finance & Global Controller at Merck & Co., Inc.

Rita A. Karachun

Rita A. Karachun

Senior Vice President-Finance & Global Controller at Merck & Co., Inc.

Biography

Presently, Rita A. Karachun holds the position of Senior Vice President-Finance & Global Controller at Merck & Co., Inc. and President for ArQule, Inc., President & Director at GlycoFi, Inc. and President & Director at Immune Design Corp. (which are all subsidiaries of Merck & Co., Inc.) and President for Inspire Pharmaceuticals, Inc.

Overview
Career Highlights

Immune Design Corp.
GlycoFi, Inc.

RelSci Relationships

3175

Number of Boards

2

Birthday

1961

Age

59

Relationships
RelSci Relationships are individuals Rita A. Karachun likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founding Partner at Polaris Partners

Relationship likelihood: Strong

Chief Executive Officer at Merck & Co., Inc.

Relationship likelihood: Strong

Executive Vice President, Global Services & Chief Financial Officer at Merck & Co., Inc.

Relationship likelihood: Strong

Chief Commercial Officer & Executive Vice President at Merck & Co., Inc.

Relationship likelihood: Strong

Chief Marketing Officer & Executive Vice President at Merck & Co., Inc.

Relationship likelihood: Strong

Secretary at Immune Design Corp.

Relationship likelihood: Strong

Executive Vice President & President, Merck Research Laboratories at Merck & Co., Inc.

Relationship likelihood: Strong

Partner at Boston Millennia Partners

Relationship likelihood: Strong

Assistant Secretary at Immune Design Corp.

Relationship likelihood: Strong

Executive Director, Corporate Responsibility at Merck & Co., Inc.

Relationship likelihood: Strong

In The News
Paths to Rita A. Karachun
Potential Connections via
Relationship Science
You
Rita A. Karachun
Senior Vice President-Finance & Global Controller at Merck & Co., Inc.
Career History
President & Director
2019 - Current

Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.

Senior Vice President-Finance & Global Controller
2009 - Current

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

President & Director
Tenure Unconfirmed

GycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$1 - $99
2013

THE CURE TAY-SACHS FOUNDATION HAS BEEN CREATED TO FUND THE RESEARCH INITIATIVES THAT SHOW PROMISE TO TREAT AND ULTIMATELY CURE TAY-SACHS DISEASE (TSD). TSD IS HEREDITARY DISEASE PASSED ON WHEN TWO CARRIER PARENTS BOTH PASS THE TAY-SACHS GENE TO THEIR CHILD. TAY-SACHS HAS THREE FORMS - THE CLASSIC OR INFANTILE FORM, THE JUVENILE ONSET FORM AND THE LATE ON-SET FORM KNOWN AS LOTS. CHILDREN INFECTED WITH THE INFANTILE OR JUVENILE FORM CURRENTLY HAVE A 100% MORTAILITY RATE - NO CHILD HAS EVER SURVIVED THIS DISEASE. WE AIM TO CHANGE THAT.

$250 - $499
2012

THE CURE TAY-SACHS FOUNDATION HAS BEEN CREATED TO FUND THE RESEARCH INITIATIVES THAT SHOW PROMISE TO TREAT AND ULTIMATELY CURE TAY-SACHS DISEASE (TSD). TSD IS HEREDITARY DISEASE PASSED ON WHEN TWO CARRIER PARENTS BOTH PASS THE TAY-SACHS GENE TO THEIR CHILD. TAY-SACHS HAS THREE FORMS - THE CLASSIC OR INFANTILE FORM, THE JUVENILE ONSET FORM AND THE LATE ON-SET FORM KNOWN AS LOTS. CHILDREN INFECTED WITH THE INFANTILE OR JUVENILE FORM CURRENTLY HAVE A 100% MORTAILITY RATE - NO CHILD HAS EVER SURVIVED THIS DISEASE. WE AIM TO CHANGE THAT.

$1 - $99
2011

THE CURE TAY-SACHS FOUNDATION HAS BEEN CREATED TO FUND THE RESEARCH INITIATIVES THAT SHOW PROMISE TO TREAT AND ULTIMATELY CURE TAY-SACHS DISEASE (TSD). TSD IS HEREDITARY DISEASE PASSED ON WHEN TWO CARRIER PARENTS BOTH PASS THE TAY-SACHS GENE TO THEIR CHILD. TAY-SACHS HAS THREE FORMS - THE CLASSIC OR INFANTILE FORM, THE JUVENILE ONSET FORM AND THE LATE ON-SET FORM KNOWN AS LOTS. CHILDREN INFECTED WITH THE INFANTILE OR JUVENILE FORM CURRENTLY HAVE A 100% MORTAILITY RATE - NO CHILD HAS EVER SURVIVED THIS DISEASE. WE AIM TO CHANGE THAT.

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations

Rita A. Karachun is affiliated with Immune Design Corp., Merck & Co., Inc., GlycoFi, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rita A. Karachun. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rita A. Karachun's profile does not indicate a business or promotional relationship of any kind between RelSci and Rita A. Karachun.